INFORMATION NECESSARY TO PREDICT INDIVIDUAL INFLIXIMAB (IFX) PHARMACOKINETICS (PK) IN PATIENTS WITH IBD

(1) Gastroenterology And Hepatology, Medical University Of Vienna, Vienna, Austria

(2) Projections Research Inc., Projections Research Inc., Phoenixville, United States



This item was part of UEG Week 2014

This item can be cited as: United European Gastroenterology Journal; 2014: 2 (Supplement 1)

You may be interested in:

INFLIXIMAB AND ADALIMUMAB IN TNF-ΑNAÏVE CROHN`S DISEASE PATIENTS: AUSTRIAN MULTICENTRE COHORT STUDY
English, Medical management, Inflammatory bowel disease, Abstract, 'IBD-ology', 2013

Categorisation:

  • Format
    • Abstract
  • Year
    • 2014